MAPT and Alzheimer disease: Liu et al. [40] administered NAM for 8 months in triple transgenic AD mice, finding NAM reduced beta amyloid (Aβ) and tau pathologies, elevated brain NAD+ levels, improved brain bioenergetics, and preserved mitochondrial functionality.